Tag: IBD
New Crohn’s Treatment Shows Promise in Major Clinical Trials
New clinical trials testing guselkumab for Crohn’s disease are showing promising results, with over half of participants achieving clinical remission and reduced steroid dependence. These studies signal a shift toward treatments that aim for both symptom relief and true intestinal healing.
New Hope in Gastroenterology: Why 2025’s Breakthroughs Matter
Q3 2025 brought major advances in gastroenterology, from breakthrough cancer immunotherapies to improved Barrett’s esophagus care. Here’s why these developments matter for the IBD community and what they mean for the future of digestive health treatment.
The Hidden Strength of Moms Living with Crohn’s Disease
Motherhood with Crohn’s disease brings unique challenges that extend far beyond typical IBD symptoms. From reproductive health concerns to fertility planning, mothers with Crohn’s navigate complex decisions while caring for their families.
New Hope: Switching Infliximab Delivery Could Change IBD Life
New research shows IBD patients can successfully switch from IV to subcutaneous infliximab while maintaining remission, with over 95% staying in remission for at least one year. This could transform treatment by offering more convenience and flexibility without sacrificing effectiveness.
Green Bay’s Walk Shows How Community Support Heals IBD Isolation
The Green Bay Take Steps Walk demonstrates how community support can combat the isolation that often accompanies IBD. Beyond fundraising for research, these events create vital connections that address the psychological challenges of living with chronic illness.
IBD Treatment Revolution: $34B Market Growth Brings New Hope
The IBD treatment market is projected to grow from $23 billion to $34 billion by 2033, driven by breakthrough biologics, precision medicine, and nanotechnology-based therapies. This unprecedented growth signals real hope for better quality of life and long-term remission for millions living with Crohn’s disease and ulcerative colitis.
Finding Hope: Michigan Medicine’s Whole-Person IBD Care Approach
University of Michigan Health’s IBD Program takes a revolutionary whole-person approach to Crohn’s and colitis care, integrating gastroenterology, surgery, nutrition, and mental health support. This comprehensive model represents a significant shift toward treating not just the disease, but the entire person living with IBD.
AI Breakthrough: New Targeted Antibiotic Offers Hope for IBD
Researchers have used AI to develop enterololin, a precision antibiotic that targets harmful IBD-related bacteria while protecting beneficial gut microbes. This breakthrough could revolutionize treatment by avoiding the collateral damage of traditional antibiotics that often worsen IBD symptoms.
Could a Common Antibiotic Be IBD’s Next Game-Changer?
New research explores how vancomycin, a familiar antibiotic, might offer unexpected hope for IBD patients. While the study focused on people with both IBD and a rare liver condition, the findings raise intriguing questions about targeting the gut microbiome for inflammation control.
AI-Designed Antibiotic Could Change IBD Treatment Forever
Researchers have developed enterololin, a new AI-designed antibiotic that targets harmful gut bacteria while preserving beneficial microbes. This precision approach could revolutionize IBD treatment by avoiding the microbiome damage typically caused by traditional antibiotics.
